Revenue grew 66% in Q4 and 59% for FY 2026, with gross margin expanding over 10 points year-over-year. FY 2027 guidance targets 44% revenue growth, continued margin improvement, and operating leverage as commercial expansion and clinical evidence drive market share gains.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.